医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集
▼×

Brentuximab Vedotin

欧盟委员会核准ADCETRIS® (brentuximab vedotin)联合AVD用于既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者，这是数十年来首个新治疗方案

欧盟委员会核准ADCETRIS® (brentuximab vedotin)联合AVD用于既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者，这是数十年来首个新治疗方案

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Brentuximab Vedotin

2019年02月14日

0

European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

European Commission Approves ADCETRIS® (brentuximab vedotin) with AVD, the First New Treatment in Decades for Adults with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma

バイオテクノロジーヘルスケア腫瘍学製薬　 TimeLine: Adults with Previously Untreated CD30 Brentuximab Vedotin European Commission Approves ADCETRIS Stage IV Hodgkin Lymphoma the First New Treatment in Decades for

2019年02月11日

0

武田获得CHMP肯定意见，接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者

武田获得CHMP肯定意见，接纳ADCETRIS® (brentuximab vedotin)联合AVD用于治疗既往未曾治疗的CD30+ IV期霍奇金淋巴瘤成人患者

バイオテクノロジーヘルスケアヘルス一般幹細胞腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin

2018年12月18日

0

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD

バイオテクノロジーヘルスケアヘルス一般幹細胞腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin For the Treatment of Adult Patients Previously Untreated CD30 Stage IV Hodgkin Lymphoma in Combination Takeda Receives Positive CHMP Opinion for ADCETRIS

2018年12月15日

0

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin ECHELON-2 Clinical Trial for ADCETRIS in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas Seattle Genetics and Takeda Present Positive Data

2018年12月04日

0

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin ECHELON-2 Clinical Trial Evaluating ADCETRIS in Frontline CD30-Expressing Peripheral T-Cell Seattle Genetics and Takeda Announce Positive

2018年10月01日

0

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin European Commission Approves ADCETRIS for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy Providing an Innovative Treatment Option

2018年01月22日

0

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: Brentuximab Vedotin ECHELON-1 Clinical Trial Evaluating ADCETRIS in Frontline Advanced Hodgkin Lymphoma Takeda and Seattle Genetics to Present Positive

2017年12月10日

0

武田的ADCETRIS® (brentuximab vedotin)获得CHMP肯定意见，用于治疗CD30阳性皮肤T细胞淋巴瘤

武田的ADCETRIS® (brentuximab vedotin)获得CHMP肯定意见，用于治疗CD30阳性皮肤T细胞淋巴瘤

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin

2017年11月17日

0

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Brentuximab Vedotin for CD30-Positive Cutaneous T-Cell Lymphoma Takeda Receives Positive CHMP Opinion for ADCETRIS

2017年11月15日

0